---
title: Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses
date: '2024-07-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38953655/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240702183523&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Human norovirus was discovered more than five decades ago and is a widespread
  cause of outbreaks of acute gastroenteritis. There are no approved vaccines or antivirals
  currently available. However, norovirus inhibitors, including capsid-specific monoclonal
  antibodies (Mabs) and nanobodies, have recently shown promising results. Several
  Mabs and nanobodies were found to inhibit norovirus replication using a human intestinal
  enteroid (HIE) culture system and/or could block norovirus attachment ...
disable_comments: true
---
Human norovirus was discovered more than five decades ago and is a widespread cause of outbreaks of acute gastroenteritis. There are no approved vaccines or antivirals currently available. However, norovirus inhibitors, including capsid-specific monoclonal antibodies (Mabs) and nanobodies, have recently shown promising results. Several Mabs and nanobodies were found to inhibit norovirus replication using a human intestinal enteroid (HIE) culture system and/or could block norovirus attachment ...